Comprehensive Stock Comparison
Compare Ainos, Inc. (AIMD) vs Cardio Diagnostics Holdings, Inc. (CDIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  CDIO | 104.5% revenue growth vs AIMD's -83.0% |
| Quality / Margins |  AIMD | -132.3% net margin vs CDIO's -415.2% |
| Stability / Safety | AIMD | Beta 1.19 vs CDIO's 2.02 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | AIMD | -38.6% vs CDIO's -62.1% |
| Efficiency (ROA) | AIMD | -65.9% ROA vs CDIO's -74.5%, ROIC -39.8% vs -222.7% |
Who Each Stock Is For
Income & stability
AIMDDividend streak 0 yrs, beta 1.19
Growth exposure
CDIORev growth 104.5%, EPS growth 53.0%, 3Y rev CAGR 238.3%
Long-term compounding (10Y)
AIMD-97.4% 10Y total return vs CDIO's -98.2%
Sleep-well-at-night portfolio
AIMDLower volatility, beta 1.19, Low D/E 77.3%, current ratio 1.10x
Defensive / Recession hedge
AIMDBeta 1.19, current ratio 1.10x
Business Model
What each company does and how it makes money
Ainos is a healthcare technology company developing point-of-care diagnostic tests and novel medical treatments. It generates revenue primarily from COVID-19 testing kits and related cloud-based management software — with additional income from its low-dose oral interferon alpha formulation and synthetic RNA platform. The company's competitive advantage lies in its integrated approach combining physical test kits with digital cloud-based management systems for healthcare providers.
Cardio Diagnostics develops and commercializes epigenetics-based clinical tests for cardiovascular disease risk assessment. It generates revenue primarily from sales of its Epi+Gen CHD test—a three-year symptomatic coronary heart disease risk assessment—to healthcare providers and through laboratory services. The company's moat lies in its proprietary epigenetic technology platform that offers more personalized cardiovascular risk prediction than traditional methods.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AIMD 4CDIO 1AIMD5/5 metricsAIMD3/3 metricsCDIO5/9 metricsAIMD4/6 metricsAIMD2/2 metricsAIMD leads in 4 of 6 categories (Financial Metrics, Valuation Metrics). CDIO leads in 1 (Profitability & Efficiency).
Financial Metrics (TTM)
AIMD is the larger business by revenue, generating $113,037 annually — 7.2x CDIO's $15,782. AIMD is the more profitable business, keeping -132.3% of every revenue dollar as net income compared to CDIO's -415.2%.
| Metric | AIMDAinos, Inc. | CDIOCardio Diagnostic… |
|---|---|---|
| RevenueTrailing 12 months | $113,037 | $15,782 |
| EBITDAEarnings before interest/tax | -$10M | -$6M |
| Net IncomeAfter-tax profit | -$15M | -$7M |
| Free Cash FlowCash after capex | -$5M | -$6M |
| Gross MarginGross profit ÷ Revenue | +82.7% | -10.3% |
| Operating MarginEBIT ÷ Revenue | -126.7% | -414.2% |
| Net MarginNet income ÷ Revenue | -132.3% | -415.2% |
| FCF MarginFCF ÷ Revenue | -41.2% | -379.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -56.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -93.9% | -15.3% |
Valuation Metrics
| Metric | AIMDAinos, Inc. | CDIOCardio Diagnostic… |
|---|---|---|
| Market CapShares × price | $7M | $141M |
| Enterprise ValueMkt cap + debt − cash | $15M | $135M |
| Trailing P/EPrice ÷ TTM EPS | -0.97x | -0.57x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 349.20x | 4054.38x |
| Price / BookPrice ÷ Book value/share | 0.92x | 14.80x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CDIO delivers a -80.4% return on equity — every $100 of shareholder capital generates $-80 in annual profit, vs $-149 for AIMD. CDIO carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to AIMD's 0.77x. On the Piotroski fundamental quality scale (0–9), CDIO scores 4/9 vs AIMD's 2/9, reflecting mixed financial health.
| Metric | AIMDAinos, Inc. | CDIOCardio Diagnostic… |
|---|---|---|
| ROE (TTM)Return on equity | -148.9% | -80.4% |
| ROA (TTM)Return on assets | -65.9% | -74.5% |
| ROICReturn on invested capital | -39.8% | -2.2% |
| ROCEReturn on capital employed | -50.0% | -123.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.77x | 0.10x |
| Net DebtTotal debt minus cash | $8M | -$7M |
| Cash & Equiv.Liquid assets | $4M | $8M |
| Total DebtShort + long-term debt | $12M | $969,863 |
| Interest CoverageEBIT ÷ Interest expense | -19.79x | -418.04x |
Total Returns (with DRIP)
A $10,000 investment in CDIO five years ago would be worth $179 today (with dividends reinvested), compared to $75 for AIMD. Over the past 12 months, AIMD leads with a -38.6% total return vs CDIO's -62.1%. The 3-year compound annual growth rate (CAGR) favors AIMD at -55.0% vs CDIO's -68.0% — a key indicator of consistent wealth creation.
| Metric | AIMDAinos, Inc. | CDIOCardio Diagnostic… |
|---|---|---|
| YTD ReturnYear-to-date | -13.7% | +85.2% |
| 1-Year ReturnPast 12 months | -38.6% | -62.1% |
| 3-Year ReturnCumulative with dividends | -90.9% | -96.7% |
| 5-Year ReturnCumulative with dividends | -99.3% | -98.2% |
| 10-Year ReturnCumulative with dividends | -97.4% | -98.2% |
| CAGR (3Y)Annualised 3-year return | -55.0% | -68.0% |
Risk & Volatility
AIMD is the less volatile stock with a 1.19 beta — it tends to amplify market swings less than CDIO's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AIMD currently trades 33.6% from its 52-week high vs CDIO's 30.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AIMDAinos, Inc. | CDIOCardio Diagnostic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.19x | 2.02x |
| 52-Week HighHighest price in past year | $4.50 | $17.39 |
| 52-Week LowLowest price in past year | $1.26 | $0.97 |
| % of 52W HighCurrent price vs 52-week peak | +33.6% | +30.2% |
| RSI (14)Momentum oscillator 0–100 | 42.8 | 64.3 |
| Avg Volume (50D)Average daily shares traded | 829K | 3.3M |
Analyst Outlook
| Metric | AIMDAinos, Inc. | CDIOCardio Diagnostic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 22 | Mar 26 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | 100 | 0.7 | -99.3% |
| Cardio Diagnostics … (CDIO) | 100.1 | 1.77 | -98.2% |
Cardio Diagnostics … (CDIO) returned -98% over 5 years vs Ainos, Inc. (AIMD)'s -99%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | $1975.00 | $20729.00 | +949.6% |
| Cardio Diagnostics … (CDIO) | $0.00 | $34890.00 | — |
Ainos, Inc.'s revenue grew from $0M (2015) to $0M (2024) — a 29.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2012 | 2024 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | -1228.0% | -717.0% | +41.6% |
| Cardio Diagnostics … (CDIO) | -688.6% | -240.3% | +65.1% |
Ainos, Inc.'s net margin went from -1228% (2012) to -717% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | -0.39 | -1.56 | -300.0% |
| Cardio Diagnostics … (CDIO) | -0.06 | -9.3 | -14522.6% |
Ainos, Inc.'s EPS grew from $-0.39 (2015) to $-1.56 (2024).
Chart 5Free Cash Flow — 5 Years
Ainos, Inc. generated $-6M FCF in 2024 (-318% vs 2021). Cardio Diagnostics Holdings, Inc. generated $-5M FCF in 2024 (-672% vs 2021).
AIMD vs CDIO: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — AIMD or CDIO?
Over the past 5 years, Cardio Diagnostics Holdings, Inc. (CDIO) delivered a total return of -98.2%, compared to -99.3% for Ainos, Inc. (AIMD). A $10,000 investment in CDIO five years ago would be worth approximately $179 today (assuming dividends reinvested). Over 10 years, the gap is even starker: AIMD returned -97.4% versus CDIO's -98.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — AIMD or CDIO?
By beta (market sensitivity over 5 years), Ainos, Inc. (AIMD) is the lower-risk stock at 1.19β versus Cardio Diagnostics Holdings, Inc.'s 2.02β — meaning CDIO is approximately 70% more volatile than AIMD relative to the S&P 500. On balance sheet safety, Cardio Diagnostics Holdings, Inc. (CDIO) carries a lower debt/equity ratio of 10% versus 77% for Ainos, Inc. — giving it more financial flexibility in a downturn.
03Which has better profit margins — AIMD or CDIO?
Cardio Diagnostics Holdings, Inc. (CDIO) is the more profitable company, earning -240.3% net margin versus -717.0% for Ainos, Inc. — meaning it keeps -240.3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDIO leads at -239.8% versus -667.7% for AIMD. At the gross margin level — before operating expenses — CDIO leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — AIMD or CDIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is AIMD or CDIO better for a retirement portfolio?
For long-horizon retirement investors, Ainos, Inc. (AIMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.19)). Cardio Diagnostics Holdings, Inc. (CDIO) carries a higher beta of 2.02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AIMD: -97.4%, CDIO: -98.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between AIMD and CDIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.